|Title:||Autoantibody recognition of an N-terminal epitope of hnRNP L marks the risk for developing HBV-related hepatocellular carcinoma||Authors:||Yau, W.-Y.
|Issue Date:||2013||Journal Volume:||94||Start page/Pages:||346-358||Source:||Journal of Proteomics||Abstract:||
Hepatocellular carcinoma (HCC) is associated with a poor prognosis and remains one of the leading causes of cancer death worldwide. Tumor-associated antigens (TAAs) and autoantibodies have been reported as potential markers in different cancers. Here, we employed an immunoproteomic approach to identify TAAs in the sera of patients with hepatitis B virus-related HCC (HBV-HCC). Immunoreactive spots were excised from 2-DE and analyzed by nano-LC-MS/MS. This analysis identified 16 HCC-associated antigens, including hnRNP L. The antigenicity of hnRNP L was further validated by immunoblotting using recombinant proteins. Autoantibodies against hnRNP L were found in 60% patients with HBV-HCC. Using sera from hnRNP L-positive patients, we found that most of these antibodies recognized glycine-rich region in the N-terminus of hnRNP L. In addition, high titers of autoantibodies against hnRNP L were found in HBV-HCC patients' sera and were associated with increased tumor size and reduced survival rate. hnRNP L protein was also found highly expressed in HCC tissue. Knockdown of hnRNP L significantly suppressed cell growth, migration, and invasion in vitro. Our results indicate that an N-terminal epitope of hnRNP L is a potential biomarker for the diagnosis of HBV-HCC and show that hnRNP L contributes to HCC progression. ? 2013 .
|DOI:||10.1016/j.jprot.2013.10.003||metadata.dc.subject.other:||amino terminal telopeptide; autoantibody; biological marker; epitope; heterogeneous nuclear ribonucleoprotein L; recombinant protein; tumor antigen; amino terminal sequence; antibody titer; antigen antibody reaction; antigenicity; article; cancer growth; cancer mortality; cancer prognosis; cancer risk; cell growth; cell invasion; cell migration; controlled study; disease association; disease marker; enzyme linked immunosorbent assay; gene silencing; hepatitis B; Hepatitis B virus; human; human cell; immunoblotting; immunoproteomics; immunoreactivity; in vitro study; liquid chromatography; liver cell carcinoma; major clinical study; mass spectrometry; priority journal; prognosis; protein analysis; proteomics; survival rate; tumor volume; AFP; Autoantibody; HCC; Hepatitis B virus; hepatocellular carcinoma; Hepatocellular carcinoma; Heterogeneous nuclear ribonucleoprotein L; heterogeneous nuclear ribonucleoprotein L; hnRNP L; Serological proteome analysis; serological proteome analysis.; SERPA; TAAs; tumor-associated antigens; Tumor-associated antigens; α-fetoprotein; Antibodies, Antinuclear; Carcinoma, Hepatocellular; Cell Line; Epitopes; Female; Hepatitis B; Hepatitis B virus; Heterogeneous-Nuclear Ribonucleoprotein L; Humans; Liver Neoplasms; Male; Tumor Markers, Biological
|Appears in Collections:||生物化學暨分子生物學科研究所|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.